<DOC>
	<DOCNO>NCT01362530</DOCNO>
	<brief_summary>This study compare safety efficacy three-day oral aprepitant regimen ( aprepitant plus ondansetron ) ondansetron alone prevention chemotherapy-induced nausea vomiting ( CINV ) 120 hour follow initiation chemotherapy pediatric participant . Those complete first cycle treatment meet certain eligibility criterion option continue 5 additional cycle open-label aprepitant .</brief_summary>
	<brief_title>A Study Safety Efficacy Aprepitant Prevention Chemotherapy-Induced Nausea Vomiting ( CINV ) Pediatric Participants ( MK-0869-208 )</brief_title>
	<detailed_description />
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Aprepitant</mesh_term>
	<mesh_term>Fosaprepitant</mesh_term>
	<mesh_term>Ondansetron</mesh_term>
	<criteria>Cycle 1 : Is 6 month 17 year age time study entry Is schedule receive chemotherapeutic agent ( ) associate moderate , high risk high risk vomit documented malignancy , chemotherapy regimen previously tolerate due vomiting Is expect receive ondansetron part antiemetic regimen If female begin menses , must negative urine pregnancy test prior randomization . A female reproductive potential agrees remain abstinent use barrier form contraception least 14 day prior , throughout , least one month follow last dose study medication If &gt; 10 year old , Karnofsky score ≥ 60 ; ≤ 10 year Lansky Play Performance score ≥ 60 Have predict life expectancy ≥ 3 month Optional Cycles 26 : Participant , opinion investigator , complete preceding cycle chemotherapy relate study procedure satisfactorily Cycle 1 : Has vomit 24 hour prior Treatment Day 1 Is schedule receive stem cell rescue therapy conjunction study related course ( ) emetogenic chemotherapy Has receive receive radiation therapy abdomen pelvis within week prior Treatment Day 1 course study Is pregnant breast feeding Is allergic aprepitant , ondansetron , 5hydroxytryptamine type3 receptor ( 5HT3 ) antagonist Has symptomatic primary metastatic CNS malignancy cause nausea and/or vomit History QT prolongation take medicinal product lead QT prolongation Has active infection ( e.g. , pneumonia ) , congestive heart failure , bradyarrhythmia , uncontrolled disease ( e.g. , diabetic ketoacidosis , gastrointestinal obstruction ) except malignancy , opinion investigator , might confound result study pose unwarranted risk administer study drug participant Has benzodiazepine opioid therapy initiate within 48 hour study drug administration , except single daily dos triazolam , temazepam , midazolam Has start systemic corticosteroid therapy within 72 hour prior study drug administration plan receive corticosteroid part chemotherapy regimen Is currently take warfarin Optional Cycles 26 : All exclusion criterion Cycle 1 apply except vomit 24 hour prior Treatment Day 1</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>